Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2020 · 10-K
Revenue$10.26M$10.26Mno prior Q4 2019 on file Net Income-$883.78K-$883.78Kno prior Q4 2019 on file EPS Diluted-$0.06-$0.06no prior Q4 2019 on file Operating Income-$1,745,946— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$808,293— Margins · derivedOperating margin-17.0%
Net margin-8.6%
ended Dec 31, 2020 · filed Mar 12, 2021 · 71 d after period end